Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Catalyst Pharmaceuticals Completes The Acquisition Of U.S. Rights To FYCOMPA (Perampanel) CIII

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive in 2023
byBenzinga Newsdesk
January 25, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy

Bolsters Presence in Neuroscience

Expected to be Accretive in 2023

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Catalyst Biosciences Announces Completion Of Business Combination With Beijing Continent Pharmaceuticals And Implementation Of Name Change And 1-For-15 Reverse Stock Split; Company Will Operate As Gyre Therapeutics, Inc. Under Trading Symbol “GYRE”

By Benzinga Newsdesk
October 30, 12:02 PM
The combined company will operate as "Gyre Therapeutics, Inc." with its common stock traded on Nasdaq under trading symbol "GYRE" effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) --

CBIO